Advanced Precision Therapies For Cancer
Proprietary Specific Neo-Antigen Peptides (SNAP) Technology Platform
Developed by Dr. Sunil Sharma and his team at the Translational Genomics Research Institute (TGen), part of the City of Hope Medical Network.
Dr. Sharma is one of the nation’s leading experts in creating anti-cancer drugs and has recently been named director of HonorHealth Research Institute’s new Center for Translational Science.
Our SNAP Technology Platform is a Major Step Forward for Targeted Therapy
- High-impact technology translating neoantigen identification to the clinic
- Direct biological confirmation of immunogenicity for individual neoantigens
- Only platform that identifies functionally validated both HLA Class I and II antigens for cancer vaccines
- Differentiated patient-specific treatment for both immunological “hot” and “cold” tumors
Team
Our Team has decades of proven experience and leadership in biopharma; supported by a network of expert advisors.
